Genmab — Januar 2019
-
Fordi den er steget flot to måneder forud fra omkring kurs 800 til næsten 1100. Så er der nogen der tager gevindsten og den falder lidt tilbage. Der er ingen aktier, der bare stiger hver dag. GEN er temmelig volatil, og udsvingene er bare store, news or not.
-
Teller...At andre analytikere og andre betragter pipelinen som "tynd" er deres problem. Jeg betragter den som meget præmatur, men spændende.
-
meget god pointe, for hver dag der går nu, mindskes håbet om, at vi har nået de 2 milliarder dollars. Gør vi ikke det, så er det en kæmpe nedjustering
-
det er jeg enig i Solsen
-
@peter12 posted this around Xmas, so not everyone may have seen it: https://www.targetedonc.com/news/stewart-gives-his-insight-on-new-data-presented-at-ash-for-multiple-myeloma
"10% of patients who are newly diagnosed are already getting daratumumab in this country. I think next year it will probably be around 50%. " -
jo, men så mangler der jo en 50million dollars stor milestone i 2018 regnskabet, det giver en stor nedjustering, og markedet har straffet disse nedjusteringer meget hårdt i 2018
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind